Copyright Reports & Markets. All rights reserved.

Global and United States Gastrointestinal Disorder Therapeutics Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Gastrointestinal Disorder Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Irritable Bowel Syndrome (IBS)
    • 1.2.3 Chronic Constipation (CC)
    • 1.2.4 Ulcerative Colitis (UC)
  • 1.3 Market by Application
    • 1.3.1 Global Gastrointestinal Disorder Therapeutics Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospitals
    • 1.3.3 Clinics
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Gastrointestinal Disorder Therapeutics Market Perspective (2015-2026)
  • 2.2 Global Gastrointestinal Disorder Therapeutics Growth Trends by Regions
    • 2.2.1 Gastrointestinal Disorder Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Gastrointestinal Disorder Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Gastrointestinal Disorder Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Gastrointestinal Disorder Therapeutics Players by Market Size
    • 3.1.1 Global Top Gastrointestinal Disorder Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Gastrointestinal Disorder Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.2 Global Gastrointestinal Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Gastrointestinal Disorder Therapeutics Revenue
  • 3.4 Global Gastrointestinal Disorder Therapeutics Market Concentration Ratio
    • 3.4.1 Global Gastrointestinal Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Gastrointestinal Disorder Therapeutics Revenue in 2019
  • 3.5 Key Players Gastrointestinal Disorder Therapeutics Area Served
  • 3.6 Key Players Gastrointestinal Disorder Therapeutics Product Solution and Service
  • 3.7 Date of Enter into Gastrointestinal Disorder Therapeutics Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Gastrointestinal Disorder Therapeutics Breakdown Data by Type (2015-2026)

  • 4.1 Global Gastrointestinal Disorder Therapeutics Historic Market Size by Type (2015-2020)
  • 4.2 Global Gastrointestinal Disorder Therapeutics Forecasted Market Size by Type (2021-2026)

5 Gastrointestinal Disorder Therapeutics Breakdown Data by Application (2015-2026)

  • 5.1 Global Gastrointestinal Disorder Therapeutics Historic Market Size by Application (2015-2020)
  • 5.2 Global Gastrointestinal Disorder Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Gastrointestinal Disorder Therapeutics Market Size (2015-2026)
  • 6.2 North America Gastrointestinal Disorder Therapeutics Market Size by Type (2015-2020)
  • 6.3 North America Gastrointestinal Disorder Therapeutics Market Size by Application (2015-2020)
  • 6.4 North America Gastrointestinal Disorder Therapeutics Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Gastrointestinal Disorder Therapeutics Market Size (2015-2026)
  • 7.2 Europe Gastrointestinal Disorder Therapeutics Market Size by Type (2015-2020)
  • 7.3 Europe Gastrointestinal Disorder Therapeutics Market Size by Application (2015-2020)
  • 7.4 Europe Gastrointestinal Disorder Therapeutics Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Gastrointestinal Disorder Therapeutics Market Size (2015-2026)
  • 8.2 China Gastrointestinal Disorder Therapeutics Market Size by Type (2015-2020)
  • 8.3 China Gastrointestinal Disorder Therapeutics Market Size by Application (2015-2020)
  • 8.4 China Gastrointestinal Disorder Therapeutics Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Gastrointestinal Disorder Therapeutics Market Size (2015-2026)
  • 9.2 Japan Gastrointestinal Disorder Therapeutics Market Size by Type (2015-2020)
  • 9.3 Japan Gastrointestinal Disorder Therapeutics Market Size by Application (2015-2020)
  • 9.4 Japan Gastrointestinal Disorder Therapeutics Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Gastrointestinal Disorder Therapeutics Market Size (2015-2026)
  • 10.2 Southeast Asia Gastrointestinal Disorder Therapeutics Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Gastrointestinal Disorder Therapeutics Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Gastrointestinal Disorder Therapeutics Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 AstraZeneca
    • 11.1.1 AstraZeneca Company Details
    • 11.1.2 AstraZeneca Business Overview
    • 11.1.3 AstraZeneca Gastrointestinal Disorder Therapeutics Introduction
    • 11.1.4 AstraZeneca Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020))
    • 11.1.5 AstraZeneca Recent Development
  • 11.2 Takeda Pharmaceutical
    • 11.2.1 Takeda Pharmaceutical Company Details
    • 11.2.2 Takeda Pharmaceutical Business Overview
    • 11.2.3 Takeda Pharmaceutical Gastrointestinal Disorder Therapeutics Introduction
    • 11.2.4 Takeda Pharmaceutical Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 11.2.5 Takeda Pharmaceutical Recent Development
  • 11.3 Johnson & Johnson
    • 11.3.1 Johnson & Johnson Company Details
    • 11.3.2 Johnson & Johnson Business Overview
    • 11.3.3 Johnson & Johnson Gastrointestinal Disorder Therapeutics Introduction
    • 11.3.4 Johnson & Johnson Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 11.3.5 Johnson & Johnson Recent Development
  • 11.4 Eisai
    • 11.4.1 Eisai Company Details
    • 11.4.2 Eisai Business Overview
    • 11.4.3 Eisai Gastrointestinal Disorder Therapeutics Introduction
    • 11.4.4 Eisai Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 11.4.5 Eisai Recent Development
  • 11.5 Abbott Laboratories
    • 11.5.1 Abbott Laboratories Company Details
    • 11.5.2 Abbott Laboratories Business Overview
    • 11.5.3 Abbott Laboratories Gastrointestinal Disorder Therapeutics Introduction
    • 11.5.4 Abbott Laboratories Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 11.5.5 Abbott Laboratories Recent Development
  • 11.6 Salix Pharmaceuticals
    • 11.6.1 Salix Pharmaceuticals Company Details
    • 11.6.2 Salix Pharmaceuticals Business Overview
    • 11.6.3 Salix Pharmaceuticals Gastrointestinal Disorder Therapeutics Introduction
    • 11.6.4 Salix Pharmaceuticals Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 11.6.5 Salix Pharmaceuticals Recent Development
  • 11.7 Bausch Health
    • 11.7.1 Bausch Health Company Details
    • 11.7.2 Bausch Health Business Overview
    • 11.7.3 Bausch Health Gastrointestinal Disorder Therapeutics Introduction
    • 11.7.4 Bausch Health Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 11.7.5 Bausch Health Recent Development
  • 11.8 Allergan
    • 11.8.1 Allergan Company Details
    • 11.8.2 Allergan Business Overview
    • 11.8.3 Allergan Gastrointestinal Disorder Therapeutics Introduction
    • 11.8.4 Allergan Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 11.8.5 Allergan Recent Development
  • 11.9 Bayer
    • 11.9.1 Bayer Company Details
    • 11.9.2 Bayer Business Overview
    • 11.9.3 Bayer Gastrointestinal Disorder Therapeutics Introduction
    • 11.9.4 Bayer Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 11.9.5 Bayer Recent Development
  • 11.10 UCB
    • 11.10.1 UCB Company Details
    • 11.10.2 UCB Business Overview
    • 11.10.3 UCB Gastrointestinal Disorder Therapeutics Introduction
    • 11.10.4 UCB Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 11.10.5 UCB Recent Development
  • 11.11 AbbVie
    • 10.11.1 AbbVie Company Details
    • 10.11.2 AbbVie Business Overview
    • 10.11.3 AbbVie Gastrointestinal Disorder Therapeutics Introduction
    • 10.11.4 AbbVie Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 10.11.5 AbbVie Recent Development
  • 11.12 GlaxoSmithKline
    • 10.12.1 GlaxoSmithKline Company Details
    • 10.12.2 GlaxoSmithKline Business Overview
    • 10.12.3 GlaxoSmithKline Gastrointestinal Disorder Therapeutics Introduction
    • 10.12.4 GlaxoSmithKline Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 10.12.5 GlaxoSmithKline Recent Development
  • 11.13 Astellas Pharma
    • 10.13.1 Astellas Pharma Company Details
    • 10.13.2 Astellas Pharma Business Overview
    • 10.13.3 Astellas Pharma Gastrointestinal Disorder Therapeutics Introduction
    • 10.13.4 Astellas Pharma Revenue in Gastrointestinal Disorder Therapeutics Business (2015-2020)
    • 10.13.5 Astellas Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Gastrointestinal Disorder Therapeutics Scope and Market Size
    Gastrointestinal Disorder Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Gastrointestinal Disorder Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Irritable Bowel Syndrome (IBS)
    Chronic Constipation (CC)
    Ulcerative Colitis (UC)

    Market segment by Application, split into
    Hospitals
    Clinics
    Others

    Based on regional and country-level analysis, the Gastrointestinal Disorder Therapeutics market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Gastrointestinal Disorder Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    AstraZeneca
    Takeda Pharmaceutical
    Johnson & Johnson
    Eisai
    Abbott Laboratories
    Salix Pharmaceuticals
    Bausch Health
    Allergan
    Bayer
    UCB
    AbbVie
    GlaxoSmithKline
    Astellas Pharma

    Buy now